These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3938352)

  • 21. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of pulsatile LH, FSH and testosterone secretion in rams by constant infusion of an LHRH agonist.
    Lincoln GA; Fraser HM; Abbott MP
    J Reprod Fertil; 1986 Jul; 77(2):587-97. PubMed ID: 3090246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC; Costantino A; Cerpolini S; Bremner WJ; Huebler D; Morselli-Labate AM; Kirsch B; Bertaccini A; Pelusi C; Pelusi G
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
    Wu FC; Balasubramanian R; Mulders TM; Coelingh-Bennink HJ
    J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM; Karpas AE; Paulsen CA; Bremner WJ
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a potent LHRH-agonist on the pituitary gonadal axis with and without testosterone substitution.
    Frick J; Aulitzky W
    Urol Res; 1986; 14(5):261-4. PubMed ID: 3099445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of simultaneous gonadotropin-releasing hormone agonist and testosterone treatment on spermatogenesis and potential fertilizing capacity in male monkeys.
    Mann DR; Gould KG; Smith MM; Duffey T; Collins DC
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1215-24. PubMed ID: 3316265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A; Venherm S; Plöger D; von Eckardstein S; Nieschlag E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC; Jouannet P; Marson J; Soumah A
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The function of the hypophyseo-gonadal system in hamadryas baboons during the tonic infusion of a luliberin agonist--buserelin].
    Goncharova ND; Goncharov NP
    Probl Endokrinol (Mosk); 1989; 35(5):68-72. PubMed ID: 2511570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine approaches to male fertility control.
    Knuth UA; Nieschlag E
    Baillieres Clin Endocrinol Metab; 1987 Feb; 1(1):113-31. PubMed ID: 3297020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.
    Valenti G; Denti L; Banchini A; Ceresini G; Ceda GP; Westel WC; Negro-Vilar A
    J Endocrinol Invest; 1990 Jun; 13(6):459-67. PubMed ID: 1701778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men.
    Martin CW; Riley SC; Everington D; Groome NP; Riemersma RA; Baird DT; Anderson RA
    Hum Reprod; 2000 Jul; 15(7):1515-24. PubMed ID: 10875859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.